Author

N. Meurice

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. T. Baker· 2 shared B. M. Nagalo· 2 shared J. M. Bogenberger· 2 shared M. Arora· 2 shared M. T. Barrett· 2 shared Y. Zhou· 2 shared A. G. Basnakian· 1 shared A. M. Abdelrahman· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. T. Baker

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers

B. M. Nagalo, Y. Zhou, E. L. Loeuillard, C. Dumbauld, O. Barro, N. Elliott, A. T. Baker, M. Arora, J. M. Bogenberger, N. Meurice, J. Petit, P. L. S. Uson Junior, F. Aslam, J. C. Chamcheu, C. C. Simoes, , M. Borad

This study characterizes Morreton virus (MORV) as a safe and effective oncolytic virotherapy for liver cancers, showing tumor regression in animal models with lower doses than VSV.

Hepatology · Jun 1, 2023Peer-reviewedImmunology

Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

M. Arora, J. M. Bogenberger, A. M. Abdelrahman, J. Yonkus, R. Alva-Ruiz, J. L. Leiting, X. Chen, P. L. Serrano Uson, C. R. Dumbauld, A. T. Baker, S. I. Gamb, J. B. Egan, Y. Zhou, B. M. Nagalo, N. Meurice, , M. J. Borad

This study shows that combining gemcitabine/cisplatin with CDK4/6 inhibitors improves efficacy and reduces toxicity in biliary tract cancers through mechanisms involving autophagy and RRM1 reduction.

bioRxiv · Oct 26, 2020Cancer Biology